Envafolimab and Surufatinib
Phase 2Small molecule
Envafolimab and Surufatinib is one of 4 small molecule programs targeting Unresectable Biliary Tract Carcinoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Unresectable Biliary Tract Carcinoma
#DrugCompanyPhaseTrials
1Adstiladrin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 2
Apatinib
LLaNova Medicines Zhejiang Co., Ltd.
Phase 2
Gemcitabine and Cisplatin
FForma Therapeutics, Inc.
Phase 2
Envafolimab and Surufatinib
TTianjin Medical University Cancer Institute and Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Envafolimab and Surufatinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details